Courage Therapeutics Awarded STTR Grant to Design Novel Anorexia Drugs
Courage Therapeutics has been awarded an STTR grant by the National Insittute of Mental Health to design novel anorexia drugs. The grant is a follow-up to research by the Cone lab at the University of Michigan that recently published in Science Translational Research that MC3R is a potential target for therapeutic development in anorexia and obesity. The effort allows for an expeditious translation of basic science into eating disorders which have remained an area of significant unmet need. - April 23, 2021
Courage Therapeutics Raises $1M for Treatment of Anorexia Nervosa and Other Related Eating Disorders
Courage Therapeutics raised $1M towards development of treatments for eating disorders including Anorexia Nervosa, ARFID, BED and genetic obesity. The company is led by Dan Housman a parent of children with eating disorders. The round was led by Michigan Biomedical Ventures. Funding will be used to test Courage’s proprietary compounds in animal models of eating disorders. The technology is based on the research on MC3R at the University of Michigan from co-founder Dr. Roger Cone’s lab. - March 24, 2021